|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.76 / 4.57|
-- Company Presentation Scheduled for June 8, 2016 at 1:00 PM PT --
Data show OCR-002 significantly reduced plasma ammonia and portal pressure in portal hypertensive rat models
Company Presentation Scheduled for April 13, 2016 at 3:40 PM ET
Company Presentation Scheduled for March 7, 2016 at 3:20 PM ET
Company Presentation Scheduled for February 9, 2016 at 10:00 AM ET
Study Demonstrated a Robust, Extended-Release Profile for All OCR-002 Prototype Extended-Release Formulations Evaluated
Ocera (OCRX) stock is gaining in late afternoon trading on Tuesday, after the bio-pharmaceutical company reported positive drug trial results.
Preliminary Pharmacokinetic Data Demonstrate Promising Extended-Release Profiles
6 Accepted Abstracts Underscore the Potential Breadth of Therapeutic Application for OCR-002
These stocks trading for under $10 a share look ready to break out and trade higher from current levels.
Company Strengthens Leadership Team With Two New Hires
Funding Extends Cash Resources to Mid-2017
Stocks with insider trader activity include SWHC, MTSI and OCRX
Stocks with insider trader activity include DXCM, FDP and OCRX